News | January 22, 2014

BioVentrix takes treatment to second European location

Implant of Revivent-TC Ventricular Enhancement System done in Czech Republic

BioVentrix Revivent-TC Heart Failure Treatment Cath Lab Structural Heart
January 22, 2014 — BioVentrix’s Revivent-TC Ventricular Enhancement System was implanted in a man via Less Invasive Ventricular Enhancement (LIVE) in Prague, Czech Republic. 
 
The procedure, which is used to reshape and reduce the left ventricle, was performed on a 64-year-old man suffering from ischemic heart failure.  Prof. Petr Neuzil and Dr. Ivo Skalsky performed the transcatheter procedure at Na Holmoce Hospital without opening the patient’s chest or using a heart-lung bypass machine.
 
“The Revivent-TC hybrid system allows treatment of both worsening heart failure patients, and those who are already very ill, without opening the chest,” said Neuzil, head of cardiology and director of the cardiac arrhythmia service. “This is a major breakthrough for this patient population that will lower the barrier to intervention for all heart failure classifications.”
 
Within three days of the LIVE procedure, the patient’s ejection fraction improved 45 percent improvement, rising from a 31 percent preoperative measurement.
 
For more information: www.bioventrix.com

Related Content

Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
Overlay Init